Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PC-A11 with laser light in recurrent head and neck squamous cell carcinoma
NL-OMON41537Phase 2Recruiting
- Sponsor
- PCI Biotech
- Start
- May 2012
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fimaporfin and bleomycin in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by PCI Biotech. Primary endpoints: Dose-limiting toxicities and Local non-progressive disease rate at 6 months. Started May 2012; status: recruiting.
02
Drugs
fimaporfinbleomycin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON41537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41537.